1. Saad Abdulmohsen Alfadly – Chairman

2. Michael Davis- Deputy Chairman

3. Faraj Saad Al-Gabani

4. Bader Fahad AlAthel

5. May Mohammed Al-Hoshan

6. Sami Suliman Alkhashan

7. Bashar Abdulaziz Abalkhail

8. Dr.Abdulaziz Saleh AlObaid

Name of the Absentee :

1. Ahmed Wazaa Alqahtani

• Bashar Abdulaziz Abalkhail - Chairman of the Nominations and Remuneration Committee

• Sami Suliman Alkhashan- Chairman of the Audit Committee

2- Approval the External Auditor Report for the fiscal year ended on 31/12/2023.

3-The Financial Statements for the fiscal year ended on 31/12/2023, was reviewed and discussed

4- Approval on the discharge of Board of Directors members for the fiscal year ended on 31/12/2023.

5- Approval on appointment of Price Waterhouse Coopers (PWC) to the auditor from among the candidates, based on the recommendation of the Audit Committee, in order to examine, review and audit the financial statements for a period of three years from the second and third quarters and the annual of the year 2024 and the first, second and third quarters and the annual of the year 2025 and the first, second and third quarters and the annual of the year 2026. and the first quarter of the year 2027 and determining his fees.

6- Approval on the Board of Directors’ recommendation to distribute cash dividends in the amount of (89,700,000) SAR to shareholders for the financial period 31/12/2023 (at 2 riyals per share and 20% of the capital), provided that the eligibility is for shareholders who own shares at the end of trading on the day of the General Assembly meeting and those registered in the company’s shareholder register at the Securities Depository Center Company (Edaa) at the end of the second trading day following the maturity date, Noting that dividends will be disbursed on 12June , 2024.

7- Approval on disbursement of (1,900,000) SAR as remuneration to Board members for the fiscal year ended on 31/12/2023.

8- Approval on transferring Statutory Reserve balance amounted (186,021,947) SAR as stated in the financial statements for the year ended on 31/12/2023 to the Retained Earnings account.

9- Approval on the employee stock program and to authorize the Board of Directors to determine the terms of this program, including the allocation price for each share offered to employees if it is for a consideration.

10- Approval on the company’s purchase of a number of its shares, up to a maximum of (160,000) shares, with the aim of allocating them to company's employees within the framework of the employee stock program, provided that the purchase is self-financing and authorizing the Board of Directors to complete the purchase process within a maximum period of (12) months from the date of the assembly’s decision. Extraordinary General Assembly, provided that the purchased shares are kept for a period not exceeding (10) years from the date of approval by the Extraordinary General Assembly. After the expiry of this period, the company follows the procedures and controls stipulated in the relevant laws and regulations.